CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 72 enrolled
Drug / intervention
ARCT-165 +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05037097
NCT05037097Phase 2Completed
CompareCT.gov

A Phase 1/2 Randomized, Observer-Blind Study of the Safety, Reactogenicity, and Immunogenicity of 3 SARS-CoV-2 RNA Vaccine Candidates in Adults Previously Vaccinated and Not Previously Vaccinated Against SARS-CoV-2

Arcturus Therapeutics, Inc.·interventional·Posted Sep 8, 2021·Updated Oct 15, 2025

In Brief

A Phase 2 clinical trial evaluating ARCT-165, ARCT-154, and 1 other intervention for COVID-19 and 2 related conditions. Completed, enrolled 72 participants across 4 sites in 3 countries.

Detailed Summary

This is a Phase 1/2, randomized, observer-blind study in healthy adults. The study will evaluate the safety, reactogenicity, and immunogenicity of 3 SARS-CoV-2 self-amplifying RNA vaccine candidates against COVID-19 in adults previously vaccinated and not previously vaccinated against SARS-CoV-2.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19, SARS-CoV-2 Infection, Corona Virus Infection
CountriesSingapore, South Africa, United States
Collaborators--

Timeline

Phase 2CompletedFinished
20222023202420252026
First PostedSep 8, 2021
Enrollment StartAug 30, 2021
Primary CompletionDec 19, 2023
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 4.8 years ago

Interventions

ARCT-165biological

Dose 3

ARCT-154biological

Dose 2

ARCT-021biological

Dose 1